المؤلفون: Abdelfatah, Rehab M.¹ (AUTHOR) r_magdy26@yahoo.com, Abdelmomen, Esraa H.² (AUTHOR), Abdelaleem, Eglal A.¹ (AUTHOR), Abdelmoety, Refaat H.³ (AUTHOR), Emam, Aml A.¹ (AUTHOR)

المصدر: BMC Chemistry. 1/7/2025, Vol. 19 Issue 1, p1-12. 12p.

مصطلحات موضوعية: *RNA polymerases, *REMDESIVIR, *CORTICOSTEROIDS, *VIRAL load, *ACETIC acid

المؤلفون: Mozaffari, Essy, Chandak, Aastha, Gottlieb, Robert, Kalil, Andre, Jiang, Heng, Oppelt, Thomas, Berry, Mark, Chima-Melton, Chidinma, Amin, Alpesh

المصدر: Clinical Infectious Diseases. 79(Supplement_4)

مصطلحات موضوعية: COVID-19, SARS-CoV-2, comorbidity, data science, elderly, immunocompromised, inverse probability of treatment weighting, omicron, propensity scores, readmission, real-world evidence, remdesivir, Humans, Adenosine Monophosphate, Alanine, Retrospective Studies, Patient Readmission, Female, Male, Aged, Middle Aged, COVID-19 Drug Treatment, COVID-19, Antiviral Agents, SARS-CoV-2, Propensity Score, United States, Adult, Hospitalization, Aged, 80 and over, Treatment Outcome

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/30p09790
https://escholarship.org/content/qt30p09790/qt30p09790.pdf

المؤلفون: Mozaffari, Essy, Chandak, Aastha, Berry, Mark, Sax, Paul, Loubet, Paul, Doi, Yohei, Amin, Alpesh, Ahuja, Neera, Müller, Veronika, Casciano, Roman, Kolditz, Martin

المصدر: Clinical Infectious Diseases. 79(Supplement_4)

مصطلحات موضوعية: COVID-19, Omicron, SARS-CoV-2, comorbidity, data science, elderly, hospitalization, pneumonia, propensity score, real-world data, real-world evidence, remdesivir, Humans, Alanine, Adenosine Monophosphate, Male, Female, Aged, Retrospective Studies, COVID-19 Drug Treatment, Middle Aged, Antiviral Agents, Hospitalization, COVID-19, United States, Hospital Mortality, SARS-CoV-2, Adult, Aged, 80 and over, Young Adult, Treatment Outcome, Adolescent

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/1nt1q0z1
https://escholarship.org/content/qt1nt1q0z1/qt1nt1q0z1.pdf

المؤلفون: Mozaffari, Essy, Chandak, Aastha, Gottlieb, Robert, Chima-Melton, Chidinma, Berry, Mark, Amin, Alpesh, Sax, Paul, Kalil, Andre

المصدر: Clinical Infectious Diseases. 79(Supplement_4)

مصطلحات موضوعية: COVID-19, SARS-CoV-2, cancer, comorbidity, data science, hematological malignancy, immunocompromised, leukemia, lymphoma, multiple myeloma, omicron, propensity score, real-world data, remdesivir, transplantation, Humans, Alanine, Adenosine Monophosphate, Male, Female, Immunocompromised Host, Middle Aged, Aged, COVID-19 Drug Treatment, COVID-19, Antiviral Agents, Hospitalization, SARS-CoV-2, Adult, Treatment Outcome, Propensity Score, Retrospective Studies, Aged, 80 and over

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/1m1783mn
https://escholarship.org/content/qt1m1783mn/qt1m1783mn.pdf

المؤلفون: Carlin, Aaron, Beadle, James, Ardanuy, Jeremy, Clark, Alex, Rhodes, Victoria, Garretson, Aaron, Murphy, Joyce, Valiaeva, Nadejda, Schooley, Robert, Frieman, Matthew, Hostetler, Karl

المصدر: Antimicrobial Agents and Chemotherapy. 68(10)

مصطلحات موضوعية: COVID-19, SARS-CoV-2, antiviral agent, broad spectrum antiviral, in vivo efficacy, lipid prodrug, mouse model, pharmacokinetics, remdesivir, remdesivir nucleoside, Animals, Prodrugs, Mice, Antiviral Agents, SARS-CoV-2, Administration, Oral, Adenosine Monophosphate, Alanine, COVID-19 Drug Treatment, Female, Humans, Phospholipids, Chlorocebus aethiops, Vero Cells, COVID-19, Disease Models, Animal, Lung, Structure-Activity Relationship, Adenosine

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/3g1195wc
https://escholarship.org/content/qt3g1195wc/qt3g1195wc.pdf

المؤلفون: Balik, M.¹ martin.balik@vfn.cz, Waldauf, P.², Jurisinova, I.¹, Svobodova, E.¹, Diblickova, M.¹, Tencer, T.², Zavora, J.^3,4, Smela, G.³, Kupidlovska, L.³, Adamkova, V.³, Fridrichova, M.⁵, Jerabkova, K.², Mikes, J.², Duska, F.², Dusek, L.⁶

المصدر: Scientific Reports. 9/6/2024, Vol. 14 Issue 1, p1-13. 13p.

مصطلحات موضوعية: *VIRAL load, *REMDESIVIR, *CRITICAL care medicine, *COVID-19, *SARS-CoV-2

المؤلفون: Unity Health Toronto, Kingston Health Sciences Centre (Kingston), Niagara Health System

المصدر: Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial

المؤلفون: The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

المساهمون: Kanecia Obie Zimmerman, Associate Professor of Pediatrics

المصدر: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Job KM, Dallmann A, Parry S, Saade G, Haas DM, Hughes B, Berens P, Chen JY, Fu C, Humphrey K, Hornik C, Balevic S, Zimmerman K, Watt K. Development of a Generic Physiologically-Based Pharmacokinetic Model for Lactation and Prediction of Maternal and Infant Exposure to Ondansetron via Breast Milk. Clin Pharmacol Ther. 2022 May;111(5):1111-1120. doi: 10.1002/cpt.2530. Epub 2022 Mar 5.

المؤلفون: International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury (PETAL) Network, Gilead Sciences

المصدر: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19 (Trial H2: Remdesivir)

المؤلفون: University of Exeter, Peninsula Clinical Trials Unit, University Hospitals of Derby and Burton NHS Foundation Trust, Aston University, University of Plymouth, Royal Devon and Exeter NHS Foundation Trust

المساهمون: Mark Faghy, Professor in Clinical Exercise Science

المصدر: An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.

المؤلفون: Sise, Meghan, Santos, Jose, Goldman, Jason, Tuttle, Katherine, Teixeira, J, Seibert, Allan, Koullias, Yiannis, Llewellyn, Joe, Regan, Sean, Zhao, Yang, Huang, Hailin, Hyland, Robert, Osinusi, Anu, Winter, Helen, Humeniuk, Rita, Hulter, Henry, Gottlieb, Robert, Fusco, Dahlene, Birne, Rita, Stancampiano, Fernando, Libertin, Claudia, Small, Catherine, Plate, Markus, McPhail, Mark

المصدر: Clinical Infectious Diseases. 79(5)

مصطلحات موضوعية: COVID-19, SARS-CoV-2, kidney impairment, remdesivir, Humans, Alanine, Adenosine Monophosphate, Male, Female, Middle Aged, COVID-19 Drug Treatment, Antiviral Agents, Double-Blind Method, Aged, SARS-CoV-2, COVID-19, Hospitalization, Acute Kidney Injury, Adult, Treatment Outcome, Respiration, Artificial, Aged, 80 and over

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/0th0g778
https://escholarship.org/content/qt0th0g778/qt0th0g778.pdf

المؤلفون: Singh, Kanal, Rubenstein, Kevin, Callier, Viviane, Shaw-Saliba, Katy, Rupert, Adam, Dewar, Robin, Laverdure, Sylvain, Highbarger, Helene, Lallemand, Perrine, Huang, Meei-Li, Jerome, Keith, Sampoleo, Reigran, Mills, Margaret, Greninger, Alexander, Juneja, Kavita, Porter, Danielle, Benson, Constance, Dempsey, Walla, El Sahly, Hana, Focht, Chris, Jilg, Nikolaus, Paules, Catharine, Rapaka, Rekha, Uyeki, Timothy, Clifford Lane, H, Beigel, John, Dodd, Lori

المصدر: The Journal of Infectious Diseases. 230(3)

مصطلحات موضوعية: COVID-19, SARS-CoV-2, antiviral efficacy, clinical trial, remdesivir, Humans, Adenosine Monophosphate, Alanine, SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, RNA, Viral, COVID-19, Male, Female, Biomarkers, Middle Aged, Viral Load, Treatment Outcome, Adult, Coronavirus Nucleocapsid Proteins, Aged, Antigens, Viral

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/2hf3r271
https://escholarship.org/content/qt2hf3r271/qt2hf3r271.pdf

المؤلفون: Cuesta, Genoveva¹ (AUTHOR), Cacho, Judit² (AUTHOR), Cucchiari, David² (AUTHOR), Herrera, Sabina³ (AUTHOR), Sempere, Abiu³ (AUTHOR), Akter, Tabassum¹ (AUTHOR), Villasante, Anna¹ (AUTHOR), Garrido, Miriam¹ (AUTHOR), Cofan, Frederic² (AUTHOR), Diekmann, Fritz² (AUTHOR), Soriano, Alex^3,4,5 (AUTHOR), Marcos, Maria Angeles^1,4,5 (AUTHOR) mmarcos@clinic.cat, Bodro, Marta^3,4,5 (AUTHOR) mbodro@clinic.cat

المصدر: Infectious Diseases & Therapy. Jul2024, Vol. 13 Issue 7, p1703-1713. 11p.

مصطلحات موضوعية: *KIDNEY transplantation, *REMDESIVIR, *COVID-19 vaccines, *SARS-CoV-2, *HOSPITAL admission & discharge, *ALPHAVIRUSES

المؤلفون: Liverpool School of Tropical Medicine, Royal Liverpool University Hospital, University of Cambridge

المصدر: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment
Griffiths G, Fitzgerald R, Jaki T, Corkhill A, Marwood E, Reynolds H, Stanton L, Ewings S, Condie S, Wrixon E, Norton A, Radford M, Yeats S, Robertson J, Darby-Dowman R, Walker L, Khoo S; UK NIHR community. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials. 2020 Jun 19;21(1):544. doi: 10.1186/s13063-020-04473-1.
Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Lalloo DG, Jacobs M, Griffiths G. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318.
Griffiths GO, FitzGerald R, Jaki T, Corkhill A, Reynolds H, Ewings S, Condie S, Tilt E, Johnson L, Radford M, Simpson C, Saunders G, Yeats S, Mozgunov P, Tansley-Hancock O, Martin K, Downs N, Eberhart I, Martin JWB, Goncalves C, Song A, Fletcher T, Byrne K, Lalloo DG, Owen A, Jacobs M, Walker L, Lyon R, Woods C, Gibney J, Chiong J, Chandiwana N, Jacob S, Lamorde M, Orrell C, Pirmohamed M, Khoo S; AGILE investigators. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. Trials. 2021 Jul 26;22(1):487. doi: 10.1186/s13063-021-05458-4.
Walker LE, FitzGerald R, Saunders G, Lyon R, Fisher M, Martin K, Eberhart I, Woods C, Ewings S, Hale C, Rajoli RKR, Else L, Dilly-Penchala S, Amara A, Lalloo DG, Jacobs M, Pertinez H, Hatchard P, Waugh R, Lawrence M, Johnson L, Fines K, Reynolds H, Rowland T, Crook R, Okenyi E, Byrne K, Mozgunov P, Jaki T, Khoo S, Owen A, Griffiths G, Fletcher TE; AGILE platform. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. Clin Pharmacol Ther. 2022 Mar;111(3):585-594. doi: 10.1002/cpt.2463. Epub 2021 Nov 13.
Khoo SH, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards CJ, Hadjiyiannakis D, Walker L, Lyon R, Shaw V, Mozgunov P, Periselneris J, Woods C, Bullock K, Hale C, Reynolds H, Downs N, Ewings S, Buadi A, Cameron D, Edwards T, Knox E, Donovan-Banfield I, Greenhalf W, Chiong J, Lavelle-Langham L, Jacobs M, Northey J, Painter W, Holman W, Lalloo DG, Tetlow M, Hiscox JA, Jaki T, Fletcher T, Griffiths G; AGILE CST-2 Study Group. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023 Feb;23(2):183-195. doi: 10.1016/S1473-3099(22)00644-2. Epub 2022 Oct 19. Erratum In: Lancet Infect Dis. 2023 Jan;23(1):e1. doi: 10.1016/S1473-3099(22)00740-X.
FitzGerald R, Dickinson L, Else L, Fletcher T, Hale C, Amara A, Walker L, Penchala SD, Lyon R, Shaw V, Greenhalf W, Bullock K, Lavelle-Langham L, Reynolds H, Painter W, Holman W, Ewings S, Griffiths G, Khoo S. Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis. 2022 Aug 24;75(1):e525-e528. doi: 10.1093/cid/ciac199.
Donovan-Banfield I, Penrice-Randal R, Goldswain H, Rzeszutek AM, Pilgrim J, Bullock K, Saunders G, Northey J, Dong X, Ryan Y, Reynolds H, Tetlow M, Walker LE, FitzGerald R, Hale C, Lyon R, Woods C, Ahmad S, Hadjiyiannakis D, Periselneris J, Knox E, Middleton C, Lavelle-Langham L, Shaw V, Greenhalf W, Edwards T, Lalloo DG, Edwards CJ, Darby AC, Carroll MW, Griffiths G, Khoo SH, Hiscox JA, Fletcher T. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. Nat Commun. 2022 Nov 26;13(1):7284. doi: 10.1038/s41467-022-34839-9.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

المصدر: Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Other URLs: http://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies

المؤلفون: Gilead Sciences

المصدر: A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

المؤلفون: Institut National de la Santé Et de la Recherche Médicale, France, World Health Organization

المساهمون: Professor Dr. Bernd Mühlbauer, Professor of Pharmacology - Head of Department

المصدر: An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

المساهمون: National Taiwan University Clinical Trial Center, Clinical professor

المصدر: Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

المصدر: Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Ader F; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.
EU-Response investigators group; Diallo A, Troseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas JR, Baratt-Due A, Melien O, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentre F, Eustace J, Saillard J, Delmas C, LeMestre S, Dumousseaux M, Costagliola D, Rottingen JA, Yazdanpanah Y. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect. 2022 Jan;28(1):1-5. doi: 10.1016/j.cmi.2021.10.011. Epub 2021 Nov 8. No abstract available.
Troseid M, Hentzien M, Ader F, Cardoso SW, Arribas JR, Molina JM, Mueller N, Hites M, Bonnet F, Manuel O, Costagliola D, Grinsztejn B, Olsen IC, Yazdapanah Y, Calmy A; EU RESPONSE; COMBINE. Immunocompromised patients have been neglected in COVID-19 trials: a call for action. Clin Microbiol Infect. 2022 Sep;28(9):1182-1183. doi: 10.1016/j.cmi.2022.05.005. Epub 2022 May 25. No abstract available.
Terzic V, Levoyer L, Figarella M, Bigagli E, Mercier N, De Gastines L, Gibowski S, Troseid M, Demotes J, Olsen IC, Hites M, Ader F, Lopez JRA, Mentre F, Esperou H, Costagliola D, Rottingen JA, Poissy J, Roze JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia. Br J Clin Pharmacol. 2023 Apr;89(4):1318-1328. doi: 10.1111/bcp.15669. Epub 2023 Feb 8.
Amstutz A, Speich B, Mentre F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Muller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schonenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023 May;11(5):453-464. doi: 10.1016/S2213-2600(22)00528-8. Epub 2023 Feb 21. Erratum In: Lancet Respir Med. 2023 Aug;11(8):e77. doi: 10.1016/S2213-2600(23)00193-5.
Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191.
Le MP, Peiffer-Smadja N, Guedj J, Neant N, Mentre F, Ader F, Yazdanpanah Y, Peytavin G; C-20-15 DisCoVeRy French Steering Committee. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. J Antimicrob Chemother. 2021 Jan 1;76(1):277-279. doi: 10.1093/jac/dkaa415. No abstract available.
Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Esperou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Paiva JA, Tacconelli E, Staub T, Greil R, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A; DisCoVeRy Safety Working group. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial. Pharmacol Res Perspect. 2023 Jun;11(3):e01072. doi: 10.1002/prp2.1072.
Fougerou-Leurent C, Delmas C, Saillard J, Dumousseaux M, Ferrane A, Mercier N, Terzic V, Le Mestre S, Dechanet A, Belhadi D, Metois A, Burdet C, Mentre F, Noret M, Diallo A, Petrov-Sanchez V, Couffin-Cadiergues S, Hites M, Ader F, Esperou H. Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study. Contemp Clin Trials. 2023 Aug;131:107267. doi: 10.1016/j.cct.2023.107267. Epub 2023 Jun 9.
Beaulieu M, Gaymard A, Massonnaud C, Peiffer-Smadja N, Bouscambert-Duchamp M, Carcelain G, Lingas G, Mentre F, Ader F, Hites M, Poignard P, Guedj J. Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. J Antimicrob Chemother. 2024 Nov 4;79(11):2887-2895. doi: 10.1093/jac/dkae301.
Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsi E, Gkirgkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; DisCoVeRy Study Group; ACTT-2 Study Group; ACTT-3 Study Group. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials. EClinicalMedicine. 2024 Feb 9;69:102472. doi: 10.1016/j.eclinm.2024.102472. eCollection 2024 Mar.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernandez Garcia C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, Garcia PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portoles A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Rottingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabie A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Le MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy study group. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Le MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentre F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.
Lingas G, Neant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentre F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J Antimicrob Chemother. 2022 Apr 27;77(5):1404-1412. doi: 10.1093/jac/dkac048.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentre F, Burdet C; DisCoVeRy Study Group. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. Lancet Infect Dis. 2022 Jun;22(6):764-765. doi: 10.1016/S1473-3099(22)00295-X. No abstract available.
Ader F; DisCoVeRy Study Group. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-beta-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results. Clin Microbiol Infect. 2022 Sep;28(9):1293-1296. doi: 10.1016/j.cmi.2022.04.016. Epub 2022 May 7. No abstract available.
Neant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Bouscambert-Duchamp M, Gagneux-Brunon A, Ader F, Mentre F, Wallet F, Burdet C, Guedj J; DisCoVeRy study group. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):2027-2037. doi: 10.1002/psp4.13051. Epub 2023 Oct 11.
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2. Erratum In: Lancet. 2022 Oct 29;400(10362):1512. doi: 10.1016/S0140-6736(22)01993-6. Lancet. 2024 Jan 13;403(10422):146. doi: 10.1016/S0140-6736(24)00005-9.
Hites M, Massonnaud CR, Lapique EL, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P, Lescure X, Troseid M, Clevenbergh P, Dalgard O, Gallien S, Gousseff M, Loubet P, Vardon-Bounes F, Visee C, Belkhir L, Botelho-Nevers E, Cabie A, Kotanidou A, Lanternier F, Rouveix-Nordon E, Silva S, Thiery G, Poignard P, Carcelain G, Diallo A, Mercier N, Terzic V, Bouscambert-Duchamp M, Gaymard A, Trabaud MA, Destras G, Josset L, Billard N, Han TH, Guedj J, Couffin-Cadiergues S, Dechanet A, Delmas C, Esperou H, Fougerou-Leurent C, Mestre SL, Metois A, Noret M, Bally I, Dergan-Dylon S, Tubiana S, Kalif O, Bergaud N, Leveau B, Eustace J, Greil R, Hajdu E, Halanova M, Paiva JA, Piekarska A, Rodriguez Bano J, Tonby K, Trojanek M, Tsiodras S, Unal S, Burdet C, Costagliola D, Yazdanpanah Y, Peiffer-Smadja N, Mentre F, Ader F; DisCoVeRy study group. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. J Infect. 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16. No abstract available.
Terzic V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Esperou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentre F, Yazdanpanah Y, Diallo A; DisCoVeRy Study Group. Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial. Clin Infect Dis. 2024 Aug 16;79(2):382-391. doi: 10.1093/cid/ciae170.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15. No abstract available.

المؤلفون: DARGAHI-MALAMIR, Mehrdad¹, HOSSEINZADEH, Mofid², KHEDRI, Reza³, HOSSEININEJAD, Hooshmand¹, BEHMANESH, Babak³, HATAMI, Ali⁴, OSKOUEI, Seyed Yashar³, MEHRABAN, Zahra¹, KOUTI, Wesam⁵, POULADZADEH, Mandana² Mandanapouladzadeh@gmail.com

المصدر: Maedica - a Journal of Clinical Medicine. 2024, Vol. 19 Issue 2, p322-329. 8p.

مصطلحات موضوعية: *COVID-19, *REMDESIVIR, *PILOT projects, *OXYGEN saturation, *FEASIBILITY studies, *CORONAVIRUS diseases